BridgeBio Reports Q2 2026 Earnings: Revenue Growth and Regulatory Milestones
BridgeBio (BBIO) reported second-quarter revenue of $243.7 million for fiscal year 2026, a significant increase from the prior-year period driven by higher product sales from Attruby. The company also noted strong brand growth with Attruby net product revenue reaching $222.4 million and sequential quarterly gains exceeding $35 million. Despite rising revenues, BridgeBio recorded a net loss of $152.2 million for the quarter compared to $181.9 million in Q2 2025. The company attributed this primarily to increased research and development expenses ($149.4 million) and selling, general, and administrative costs ($186.3 million), reflecting ongoing investments ahead of product launches. BridgeBio also highlighted several regulatory milestones: the FDA accepted BBP-418 for limb-girdle muscular dystrophy with a PDUFA date in November 2026; Encaleret received priority review for autosomal dominant hypocalcemia type 1, with an action date set for May 2027. Infigratinib's NDA was submitted for achondroplasia, targeting U.S. launch by mid-2027.
Tickers: $BBIO
Topics: cash position FDA milestones net loss R&D expenses revenue